Immutep Ltd Clinical Results Webinar Transcript
Okay. Good morning, everybody. Good morning, ladies and gentlemen, and thank you for joining us for the Immutep webcast to discuss the company's new clinical data released today regarding Cohort B of the TACTI-003 trial. My name is Paul Sanger, and I will be your moderator today.
(Event Instructions) Let's get started. I would now like to hand over the call to Marc Voigt, Immutep's CEO, to start the presentation. Marc, please go ahead.
Yeah. Thank you, Paul, and welcome, everyone, and we appreciate that you are taking the time again. We are excited to provide this update on TACTI-003 Cohort B on the heels of the oral presentation earlier today at the ESMO virtual plenary session. These ESMO sessions are presentations of the latest original scientific data from clinical trials, and as it relates to Phase IIs, ESMO select trials, which demonstrate remarkable therapeutic benefit, scientific insight, or progress in the area of unmet medical need, and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |